TB Alliance to Present Research at ICAAC 2012

Workshop on Clinical Pharmacology of TB Drugs to Precede Conference

September 5, 2012

The TB Alliance and its partners will be presenting recent advances in TB research and development at the ICAAC 2012 conference. Posters and presentations will detail important findings from the The University of Auckland and TB Alliance’s lead preclinical TB drug candidate, the nitroimidazole, TBA-354.

A full schedule of TB Alliance presentations is below. Please join us if you are attending the conference as well.


· TBA-354: A Next Generation Nitroimidazole for Treatment of Drug Sensitive and Drug Resistant Tuberculosis

Description: Nitroimidazoles represent a promising new class of anti-tubercular agents with potential for the treatment of drug sensitive and drug resistant disease. Two first generation compounds (PA-824 and OPC67683) are currently in clinical development. To maximize the potential of this class for TB, TB Alliance has identified a next generation nitroimidazole, known as TBA-354, for preclinical development.

Session Title: New Treatments for Mycobacterium tuberculosis Infections
Session Day/Time: 9/9/2012 4:00 PM - 9/9/2012 6:00 PM
Presentation Day/Time: 5:30pm - 6:00pm
Presentation Number: 438
Location: Room 122
Presenter: Anna Upton (TB Alliance)

· TBA-354, A New Generation Niroimidazole for Both Drug-Sensitive and Drug-Resistant TB

Description: TB Alliance Chief Scientific Officer, Dr. Zhenkun Ma, presents an overview of data presented at ICAAC regarding preclinical TB drug candidate, TBA-354.

Session Title: Early New Antimicrobial Agents
Session Type: Poster Summary Session
Session Day/Time: Sunday, Sep 09, 2012, 1:45 PM - 3:45 PM
Location: Room 104
Presenter: Zhenkun Ma (TB Alliance)

· New Drugs in the Clinical Pipeline for TB

Session Title: New Issues in the Management of MDR/XDR TB
Presentation Day/Time: 9/10/2012 9:50 AM - 9/10/2012 10:10 AM: 5:30pm - 6:00pm
Presentation Number: 537
Location: Esplanade Ballroom 306
Presenter: Mel Spigelman

Poster Sessions

This series of poster presentations covers various in vitro and in vivo data and scientific information relating to the TB drug candidate, TBA-354, presented by the TB Alliance and partners.

The New Approaches in Mycobacterial Therapy Poster Sessions will take place on Monday, September 10, 11-15am - 1:15pm in the Exhibit Hall.

· #1: Anti-tuberculosis in Vitro Activity of the Nitroimidazole TBA-354
Control Number: 1816
Presenter: Sang Cho (University of Illinois at Chicago)

· #2: In vivo Anti-tuberculosis Activity of the Nitroimidazole TBA-354 Against Acute and Chronic Murine Tuberculosis
Control Number: 1824
Presenter: Anna Upton (TB Alliance)

· #3: Activity of the Nitroimidazole TBA-354 Alone and in a Novel Drug Regimen in Two Murine Models of Tuberculosis
Control Number: 1827
Presenter: Eric Nuermberger (Johns Hopkins University)

· #4: In Vitro and in vivo Evaluation of the Phototoxic Potential of the Nitroimidazole TBA-354
Control Number: 2177
Presenter: Diana Severynse-Stevens (Research Triangle Institute)

· #5: TBA-354: Process Chemistry Optimization for Large Scale API Production to Support IND-Enabling Development
Control Number: 2186
Presenter: Chris Cooper (TB Alliance)

· #6: In vitro Profiling of the Absorption, Distribution, Metabolism and Excretion (ADME) Properties of the Nitroimidazole TBA-354
Control Number: 2192
Presenter: Elliott Pauli (Research Triangle Institute)

· #7: Preclinical Pharmacokinetic Studies of the Nitroimidazole TBA-354 in Mice, Rats and Dogs
Control Number: 2199
Presenter: TJ Yang (TB Alliance)

Related events

5th International Workshop on Clinical Pharmacology of Tuberculosis Drugs
8 September 2012 | San Francisco

The TB pharmacology workshop offers a unique platform to discuss the latest important scientific findings in the TB clinical pharmacology field, by bringing experts together and having them present the latest developments. The format of the workshop allows ample time for lively interactions in an intimate set-up. Topics that will be addressed include pharmacokinetics and pharmacodynamics of new/approved TB drugs, PK/PD modeling and Drug-drug and drug-disease interactions.